Department of Oncology, Skane University Hospital, Lund, Sweden.
Leuk Lymphoma. 2011 Oct;52(10):1929-35. doi: 10.3109/10428194.2011.587560. Epub 2011 Jun 24.
Abstract In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7-0.9) for patients diagnosed during the latest time period, 2006-2010, also when corrected for prognostic factors as above. Estimated OS at 3 years was 62%, compared to 47% for patients diagnosed earlier (p < 0.01). The reasons for this dramatic improvement in OS are not yet clear, but may be due to the introduction of specific and more potent therapeutic regimens.
近年来，针对套细胞淋巴瘤（MCL）的强化化疗方案与生存时间的延长有关。本研究旨在探讨 MCL 的预后因素，并评估人群水平上的生存改善情况。该队列纳入了瑞典淋巴瘤登记处于 2000 年 1 月 1 日至 2010 年 3 月 31 日期间诊断为 MCL 的所有患者。共确定了 785 例 MCL 患者。在多变量分析中，年龄、体能状态和 B 症状是总生存（OS）的显著预后因素。此外，与更早诊断的患者（诊断时间为 2000-2005 年）相比，最近诊断（2006-2010 年）的患者 OS 明显改善（风险比 0.8，95%置信区间 0.7-0.9），同时校正了上述预后因素。估计 3 年 OS 为 62%，而早期诊断的患者为 47%（p<0.01）。OS 显著改善的原因尚不清楚，但可能是由于引入了特异性和更有效的治疗方案。
